(Alliance News) - Destiny Pharma PLC said Monday it has completed the initial phase of its project with MedPharm Ltd to develop new topical formulations of the company's XFâ€platform drugs.
The collaboration was first announced in March last year.
MedPharm is a contract provider of topical and transdermal product design and formulation development services.
"The project has identified a range of new, stable XF formulations with promising drug release profiles and scope for delivery of XF drugs (including clinical stage XF-73, XF-70 and DPD-207 compounds) designed to treat dermal and ocular infections," Destiny Pharma said.
These formulations will form the basis of XF drug delivery for Destiny Pharma's pre-clinical and clinical programmes and treatments for both acute and chronic infections, the company added.
Certain formulations will also be incorporated into ongoing funded projects.
Destiny Pharma Chief Executive Neil Clark said: "We are pleased to announce positive progress made during 2019 to develop new formulations of XF drugs from our novel antimicrobial XFâ€platform. There is an unmet medical need for novel anti-infectives that address dermal and ocular infections with a significantly reduced potential for generating antimicrobial resistance.
"We look forward to continuing to work with MedPharm to support the expansion of our pipeline as we take select formulations into our ongoing preâ€clinical and clinical studies. Our lead drug candidate from the XF-platform, XFâ€73 nasal gel, for the prevention of postâ€surgical infections, is currently in Phase 2b development with data expected in mid-2020."
Shares in Destiny Pharma were 4.5% higher in London on Monday at 45.44 pence each.
By Paul McGowan; paulmcgowan@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Destiny Pharma. (DEST)